This company has been marked as potentially delisted and may not be actively trading. Vallon Pharmaceuticals (VLON) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VLON vs. OSTX, PYRGF, ATNM, ELYM, NBRV, AADI, EGRX, HILS, NNVC, and TAOXShould you be buying Vallon Pharmaceuticals stock or one of its competitors? The main competitors of Vallon Pharmaceuticals include OS Therapies (OSTX), PyroGenesis Canada (PYRGF), Actinium Pharmaceuticals (ATNM), Eliem Therapeutics (ELYM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Eagle Pharmaceuticals (EGRX), Hillstream BioPharma (HILS), NanoViricides (NNVC), and Synaptogenix (TAOX). Vallon Pharmaceuticals vs. Its Competitors OS Therapies PyroGenesis Canada Actinium Pharmaceuticals Eliem Therapeutics Nabriva Therapeutics Aadi Bioscience Eagle Pharmaceuticals Hillstream BioPharma NanoViricides Synaptogenix Vallon Pharmaceuticals (NASDAQ:VLON) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability. Do institutionals and insiders hold more shares of VLON or OSTX? 8.7% of Vallon Pharmaceuticals shares are held by institutional investors. 37.3% of Vallon Pharmaceuticals shares are held by company insiders. Comparatively, 13.8% of OS Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger valuation and earnings, VLON or OSTX? Vallon Pharmaceuticals has higher revenue and earnings than OS Therapies. OS Therapies is trading at a lower price-to-earnings ratio than Vallon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVallon Pharmaceuticals$100K198.19-$7.02M-$0.78-1.88OS TherapiesN/AN/A-$7.79M-$0.86-2.50 Does the media favor VLON or OSTX? In the previous week, OS Therapies had 4 more articles in the media than Vallon Pharmaceuticals. MarketBeat recorded 4 mentions for OS Therapies and 0 mentions for Vallon Pharmaceuticals. Vallon Pharmaceuticals' average media sentiment score of 0.00 beat OS Therapies' score of -0.18 indicating that Vallon Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Vallon Pharmaceuticals Neutral OS Therapies Neutral Is VLON or OSTX more profitable? OS Therapies' return on equity of 0.00% beat Vallon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vallon PharmaceuticalsN/A -230.48% -124.89% OS Therapies N/A N/A -569.57% Do analysts recommend VLON or OSTX? OS Therapies has a consensus price target of $18.00, suggesting a potential upside of 737.21%. Given OS Therapies' stronger consensus rating and higher possible upside, analysts plainly believe OS Therapies is more favorable than Vallon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vallon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 SummaryVallon Pharmaceuticals beats OS Therapies on 8 of the 14 factors compared between the two stocks. Get Vallon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VLON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VLON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VLON vs. The Competition Export to ExcelMetricVallon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.82M$806.50M$5.76B$9.65BDividend YieldN/A4.84%3.91%4.09%P/E Ratio-1.881.1530.7825.12Price / Sales198.1925.87457.76116.61Price / CashN/A19.5625.2228.45Price / Book8.176.609.365.94Net Income-$7.02M-$4.93M$3.26B$265.56M Vallon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VLONVallon PharmaceuticalsN/A$1.47+5.8%N/A+183.0%$19.82M$100K-1.883OSTXOS Therapies2.218 of 5 stars$1.88+5.6%$18.00+857.4%-37.4%$52.82MN/A-2.19N/ANews CoveragePYRGFPyroGenesis CanadaN/A$0.27-0.8%N/A-59.5%$51.37M$9.14M-4.5790ATNMActinium Pharmaceuticals2.9296 of 5 stars$1.60+6.0%$4.50+181.3%-6.0%$49.91MN/A-1.1530Positive NewsShort Interest ↓ELYMEliem TherapeuticsN/A$1.61-2.4%N/A-69.1%$47.90MN/A-3.049Gap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi Bioscience0.5075 of 5 stars$1.71+1.2%$1.67-2.5%+8.8%$42.23M$25.07M-0.7540EGRXEagle Pharmaceuticals1.7703 of 5 stars$3.20flatN/AN/A$41.56M$257.55M0.00100News CoverageGap DownHILSHillstream BioPharmaN/A$1.40+16.7%N/A-54.2%$24.64MN/A-1.941NNVCNanoViricides0.7175 of 5 stars$1.50-2.6%N/A-29.5%$24.11MN/A-2.0820News CoverageTAOXSynaptogenixN/A$9.56+14.6%N/AN/A$13.29MN/A-0.954News CoverageEarnings ReportAnalyst Downgrade Related Companies and Tools Related Companies OSTX Alternatives PYRGF Alternatives ATNM Alternatives ELYM Alternatives NBRV Alternatives AADI Alternatives EGRX Alternatives HILS Alternatives NNVC Alternatives TAOX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VLON) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vallon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vallon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access